Table 3.
In-study trends in laboratory parameters associated with the metabolic syndrome (secondary efficacy endpoints). All results expressed as mmol/L unless indicated otherwise. Data are expressed as mean ± SD.
| Total patients | N = 5603 |
|---|---|
| Fasting plasma glucose | |
| At study start | 6.8 ± 2.1 |
| At study end | 6.2 ± 1.6 |
| In-study change | −0.8 ± 1.6 |
| Triglycerides | |
| At study start | 2.4 ± 1.1 |
| At study end | 2.0 ± 0.9 |
| In-study change | −0.6 ± 1.0 |
| Cholesterol | |
| At study start | 5.8 ± 1.1 |
| At study end | 5.2 ± 0.9 |
| In-study change | −0.7 ± 1.0 |
| HDL-cholesterol | |
| At study start | 1.2 ± 0.5 |
| At study end | 1.3 ± 0.5 |
| In-study change | 0.1 ± 0.5 |
| LDL-cholesterol | |
| At study start | 3.5 ± 1.1 |
| At study end | 3.0 ± 0.9 |
| In-study change | −0.5 ± 0.9 |
| Creatinine | |
| At study start | 0.09 ± 0.06 |
| At study end | 0.10 ± 0.07 |
| In-study change | 0.01 ± 0.04 |
| Urinary albumin | |
| At study start | 92.7 ± 191.6 |
| At study end | 83.3 ± 205.5 |
| In-study change | −7.6 ± 153.1 |
| Body weight (kg) | |
| At study start | 92.0 ± 15.6 |
| At study end | 90.0 ± 15.3 |
| In-study change | −2.1 ± 5.4 |